ArticleInfectious Disease Modelling2025
Estimating cumulative infection rate of COVID-19 after adjusting the dynamic zero-COVID policy in China.
Article in Infectious Disease Modelling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- China's post-zero-COVID Omicron wave: A Bayesian analysis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Humoral immunity and clinical characteristics of Chinese college students experiencing a BA.5/BF.7 and XBB.1.5 wave.Scientific reports · 2025Article
- SARS-CoV-2 N protein exerts antitumor effects in NSCLC by inducing DNA damage and augmenting chemotherapeutic sensitivity.Medical oncology (Northwood, London, England) · 2025Article
- Comparison of plasma sterilizer and conventional laminar flow room in allogeneic hematopoietic stem cell transplant recipients.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: At the end of 2022, China adjusted its coronavirus disease 2019 (COVID-19) prevention and control strategy. How this adjustment affected the cumulative infection rate is debated, and how second booster dose vaccination affected the pandemic remains unclear. Methods: We collected COVID-19 case data for China's mainland from December 7, 2022, to January 7, 2023, reported by the World Health Organization. We also collected cumulative infection rate data from five large-scale population-based surveys. Next, we developed a dynamic transmission compartment model to characterize the COVID-19 pandemic and to estimate the cumulative infection rate. In addition, we estimated the impact of second booster vaccination on the pandemic by examining nine scenarios with different vaccination coverages (0%, 20%, and 40%) and vaccine effectiveness (30%, 50%, and 70%). Results: By January 7, 2023, when COVID-19 was classified as a Class B infectious disease, the cumulative infection rate of the Omicron variant nationwide had reached 84.11% (95% confidence interval [CI]: 78.13%-90.08%). We estimated that the cumulative infection rates reached 50.50% (95% CI: 39.58%-61.43%), 56.15% (95% CI: 49.05%-67.22%), 73.82% (95% CI: 64.63%-83.02%), 75.76% (95% CI: 67.02%-84.50%), and 84.99% (95% CI: 79.45%-90.53%) on December 19, 20, 25, and 26, 2022, and on January 15, 2023, respectively. These results are similar to those of the population survey conducted on the corresponding dates, that is 46.93%, 61%, 63.52%, 74%, and 84.7%, respectively. In addition, we estimated that by January 7, 2023, the cumulative infection rate decreased to 29.55% (64.25%) if vaccination coverage and the effectiveness of second booster vaccination were 40% (20%) and 70% (30%), respectively. Conclusion: We estimate that, in late 2022, the cumulative infection rate was approximately 84% and that second booster vaccination before the policy adjustment was effective in reducing this rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.